

FREEDOM OF INFORMATION REQUEST

RF23-670

We can confirm East Kent Hospitals University NHS Foundation Trust (EKHUFT) holds the information you have requested. Please see the below answers in bold.

Please answer the questions with regards to NHS patients, i.e., excluding patients that received treatment as part of clinical trials or private healthcare.

Patients with acute myeloid leukaemia (AML)

1. How many patients with AML, in total, have been treated with the following therapies during the last 6 months, irrespective of start date or line of therapy?

Azacitidine monotherapy	12
Low dose cytarabine (LoDAC) monotherapy	2
Venetoclax + azacitidine	12
Venetoclax + LoDAC	0
Ivosidenib	0
Intensive chemotherapy-based regimen	10
Other	0

2. How many newly diagnosed patients with AML have started first-line treatment with the following therapies during the last 6 months?

Azacitidine monotherapy	3
Low dose cytarabine (LoDAC) monotherapy	0
Venetoclax + azacitidine	5
Venetoclax + LoDAC	0
Ivosidenib	0
Intensive chemotherapy based regimen	6
Other	0

Note: this should only include patients who have started first-line treatment during the 6-month window

3. (a) Of the patients with AML treated with venetoclax (venetoclax + azacitidine or venetoclax + LoDAC) in the last 6 months, how many are approved for treatment via Blueteq?

5 patients

Patients with chronic lymphocytic leukaemia (CLL)

4. How many patients with CLL have received treatment with venetoclax in the past 6 months (including venetoclax monotherapy, venetoclax + rituximab, venetoclax + obinutuzumab or venetoclax + ibrutinib)?

Note: this should include patients who started treatment prior to the 6-month window

14 patients

5. How many patients with CLL who were new to all lines of treatment received venetoclax in the past 6 months (including venetoclax monotherapy, venetoclax + rituximab, venetoclax + obinutuzumab or venetoclax + ibrutinib)?

Note: this should include only patients who have started treatment during the 6-month window

5 patients

(DATE OF RESPONSE: 05 DECEMBER 2023)